2026-01-10 - Analysis Report
Here's a comprehensive analysis of Merck & Co Inc (MRK) based on the provided data:

**0. Overview:**

Merck & Co Inc is a global pharmaceutical company focused on research, development, manufacturing, and marketing of a wide range of innovative health solutions.

**1. Return Rate Comparison vs. S&P 500 (VOO):**

*   **MRK Cumulative Return:** 28.16%
*   **VOO Cumulative Return:** 92.74%
*   **Divergence:** -68.1 (Relative Divergence: 23.8)

**Analysis:**

MRK has significantly underperformed the S&P 500 over the period examined, with a large negative divergence. The relative divergence of 23.8 suggests this underperformance is closer to the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha | Beta | Cap(B) |
|------------|--------|--------|-------|------|--------|
| 2016-2018  | 24.0%  | 14.7%  | 21.0% | 0.7  | 181.4  |
| 2017-2019  | 37.0%  | 14.7%  | 20.0% | 0.7  | 215.9  |
| 2018-2020  | 13.0%  | 19.3%  | -8.0% | 0.7  | 194.2  |
| 2019-2021  | 0.0%   | 19.3%  | -43.0% | 0.6  | 190.6  |
| 2020-2022  | 14.0%  | 16.3%  | 16.0% | 0.5  | 276.0  |
| 2021-2023  | 31.0%  | 14.3%  | 30.0% | 0.3  | 271.2  |
| 2022-2024  | -5.0%  | 24.9%  | -24.0% | 0.3  | 247.4  |
| 2023-2025  | -24.0% | 39.0%  | -86.0% | 0.3  | 261.8  |

*   **Alpha:**  Alpha has been highly variable, with recent periods showing significant negative alpha, indicating underperformance relative to its risk-adjusted expected return.
*   **Beta:** Beta is consistently below 1, suggesting MRK is less volatile than the overall market (S&P 500). Beta has been trending down, indicating it has become less corelated with the market.
*   **CAGR:** CAGR is variable, with recent periods showing significant negative return.
*   **MDD:** MDD is variable, with recent periods showing the significant percentage of maximum drawdown.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 110.99
*   **Last-market Data:** Price: 110.53, Previous Close: 110.99, Change: -0.41
*   **5-day SMA:** 108.47
*   **20-day SMA:** 103.985
*   **60-day SMA:** 95.9877

**Analysis:**

The current price is above all three moving averages, suggesting a short-term upward trend. The 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA, further confirming this uptrend. The recent small price decrease may reflect the fluctuation issue.

**3. RSI, PPO and Other Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 88.37 (Overbought)
*   **PPO:** 0.2392
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2026-01-05)
*   **Recent (20 days) relative divergence change:** 2.0 (+): 단기상승 (Short-term Increase)
*   **Expected Return (%):** -27.3 (Long-term)

**Analysis:**

*   The RSI indicates the stock is currently overbought, suggesting a potential pullback in the near term.
*   The PPO being positive indicates the short-term moving average is above the long-term moving average.
*   The Hybrid Signal suggests a buying opportunity.
*   The negative expected return over the long term indicates that analysts believe the stock is currently overvalued, despite recent price increases. The divergence increasing recently indicates a short-term increase.

**4. Recent News & Significant Events:**

*   **Takeover Buzz:** News articles mention potential takeover interest in Revolution Medicines, with Merck potentially being a suitor. This could drive short-term price volatility.
*   **Analyst Target Lift:** Morgan Stanley increased its price target on MRK, citing an improved biopharma outlook. This is a positive sign.
*   **Stock Position Cut:** The State of Alaska Department of Revenue cut its position in MRK, which could be a negative signal.
*   **CDC Vaccine Shift:** News regarding the CDC's vaccine strategies may impact Merck, depending on the specific changes and Merck's involvement in relevant vaccine development/production.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.90)
*   **Target Price:** Average: $113.33, High: $135.00, Low: $83.00
*   **Recent Rating Changes:** No changes are provided

**Analysis:**

The analyst consensus is positive, with a "Buy" rating and an average target price slightly above the current price. The high target price suggests some analysts see significant upside potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

**Analysis:**

Revenues and EPS generally are trending upward. The EPS has significantly increased in the most recent period.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|----------------|
| 2025-09-30   | $17.28B   | 77.69%         |
| 2025-06-30   | $15.81B   | 77.50%         |
| 2025-03-31   | $15.53B   | 77.98%         |
| 2024-12-31   | $15.62B   | 75.50%         |
| 2024-09-30   | $16.66B   | 75.51%         |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $51.85B   | 11.16%  |
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |

**Analysis:**

*   Revenue is generally increasing.
*   Profit margins are high and relatively stable, indicating strong profitability.
*   Equity is increasing, suggesting the company is growing its net assets.
*   ROE is also increasing, showing improved returns on equity.

**7. Comprehensive Analysis:**

MRK exhibits a mixed outlook. While it has underperformed the S&P 500 significantly in the past, recent indicators show potential for short-term gains:

*   **Positive Factors:**
    *   Recent price uptrend (price above SMAs)
    *   "Buy" analyst consensus and rising target price
    *   Strong revenue and profit margin growth
    *   Potential takeover interest from Revolution Medicines
    *   Hybrid Signal indicating a buy.
*   **Negative Factors:**
    *   Underperformance compared to the S&P 500
    *   Overbought RSI, suggesting a potential pullback
    *   Negative long-term expected return
    *   Stock position cut by the State of Alaska Department of Revenue.

**Summary:**

Based on the data, MRK is potentially a mixed bag. Recent earnings and profitability trends are promising. There are potential catalysts (takeover rumors, analyst upgrades) that could push the stock higher. However, the negative expected return suggests caution. The overbought RSI implies a high price. Given the available information, short term is high, but there's risk for the long run, especially compared to the market.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.